A powder inhaler includes a casing having a mouthpiece and housing an inhalation channel connected to an opening of the mouthpiece, a container for storing a powdered medicament and placed in the casing, a cover engageable with the casing to close the mouthpiece. The cover includes a sealing element made of a material that is more deformable than a material of the mouthpiece such that, when the cover is engaged with the casing and closes the mouthpiece, a main portion of the sealing element is coupled to the opening to tight close the opening.
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising signs of cardboard; printed teaching materials;
informational sheets; printed promotional material;
advertisement boards of card; pharmaceutical information
leaflets; newspapers; books; manuals [handbooks]; pamphlets;
professional magazines; journals; educational publications;
printed educational materials; magazines [periodicals];
printed reports; printed research reports; printed matter;
prints. Conducting of educational seminars relating to medical
matters; advice relating to medical training; courses
(training -) relating to science; courses (training -)
relating to medicine; arranging and conducting of workshops
[training]; training; personnel training; teaching;
education services relating to pharmacy; publishing of
scientific papers; production of audio/visual presentations;
publishing of journals, books and handbooks in the field of
medicine; publication of the results of clinical trials for
pharmaceutical preparations; publishing and issuing
scientific papers in relation to medical technology;
organisation of conferences and symposia in the field of
medical science; organisation of seminars; organization of
seminars and conventions in the field of medicine;
organisation of training courses; arranging of lectures;
workshops for educational purposes; education services
relating to medicine; arranging of presentations for
educational purposes; educational seminars; training
services in the field of medical disorders and their
treatment; educational services in the healthcare sector;
production of course material distributed at professional
seminars; teaching in the field of medicine; medical
education services; teaching services relating to the
medical field. Advisory services relating to science; technological
consultancy; consultancy pertaining to pharmacology;
consultancy relating to pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; providing information about the results of clinical
trials for pharmaceutical products; biological research;
biological research and analysis; advisory services relating
to biochemistry; research on the subject of pharmaceuticals;
pharmaceutical product evaluation; pharmaceutical products
development; biomedical research services; information
technology services for the pharmaceutical and healthcare
industries; research and development for the pharmaceutical
industry. Consulting services relating to health care; pharmaceutical
advice; medication counseling; professional consultancy
relating to health; providing news and information in the
field of medicine; providing health care information via a
global computer network; medical information; remote
monitoring of medical data for medical diagnosis and
treatment; consulting services relating to health care;
providing medical information; medical and healthcare
services; medical services for the diagnosis of conditions
of the human body; medical screening; pharmaceutical
services; medical health assessment services; medical and
healthcare clinics; advisory services relating to
pharmaceuticals.
Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
5.
TRIAZOLONE DERIVATIVE SALT AS NEUTROPHIL ELASTASE INHIBITOR
The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as medicament; the invention also relates to its synthesis process and pharmaceutical compositions thereof. The invention also relates to the process for the isolation by crystallization of the compound (I). The invention also relates to a crystal form of a compound of formula (I).
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 11/00 - Drugs for disorders of the respiratory system
C07C 65/11 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
6.
DRY POWDER FORMULATIONS FILLED IN AN INHALER WITH IMPROVED RESISTANCE TO HUMIDITY
A drug product includes a multidose dry powder inhalation device. The device has a medicament chamber and a desiccant chamber adjacent to the medicament chamber, and a pharmaceutical composition therein. The pharmaceutical composition includes a pharmaceutically acceptable salt of tanimilast. The desiccant chamber is filled with molecular sieves.
The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as a medicament. The present invention also relates to pharmaceutical compositions comprising the novel triazolone derivative salt and one or more pharmaceutically acceptable carriers and/or excipients thereof and to their use as medicament.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 11/00 - Drugs for disorders of the respiratory system
C07C 65/11 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
8.
DRY POWDER FORMULATIONS FILLED IN AN INHALER WITH IMPROVED RESISTANCE TO HUMIDITY
A drug product includes a multidose dry powder inhalation device. The device has a medicament chamber and a desiccant chamber adjacent to the medicament chamber, and a pharmaceutical composition therein. The pharmaceutical composition includes a pharmaceutically acceptable salt of formoterol, optionally in combination with a pharmaceutically acceptable salt of glycopyrronium and/or beclomethasone dipropionate. The desiccant chamber is filled with molecular sieves.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A powder inhaler includes a casing having a mouthpiece, an inhalation channel, a container for a powdered medicament, and a metering device with a shuttle having a dosing recess. The shuttle is movable between a filling position, in which the dosing recess is in alignment with an opening of the container to be filled with a dose of the powdered medicament, and an inhalation position, in which the dosing recess is in alignment with the inhalation channel, for enabling inhalation of the dose of the powdered medicament contained in the dosing recess through the mouthpiece. A sealing device is operationally active at a coupling zone of the shuttle with the container when the shuttle is in the filling position, the coupling zone circumscribing the dosing recess and the opening.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; pharmaceutical preparations for the
treatment of pulmonology diseases and disorders, fibrotic
diseases and disorders and vascular diseases and disorders.
11.
ELECTRONIC MODULE FOR A METERED DOSE INHALER AND METERED DOSE INHALER ASSEMBLY COMPRISING THE ELECTRONIC MODULE
An electronic module for a metered dose inhaler comprises a casing (10) having an external surface (17) provided with a pressure detection point (16), an electronic unit (11) and a pressure sensor (13) enclosed in the casing (10). The pressure sensor (13) is operatively connected to the electronic unit (11) and to the pressure detection point (16). The casing (10) comprises two hooks (19) configured to engage an edge (9) of a housing (6) of a metered dose inhaler (2) accommodating a canister (5) containing a drug formulation to be dispensed. The pressure detection point (16) is located between the two hooks (19). The electronic module is attachable to the metered dose inhaler.
An electronic module for a metered dose inhaler comprises a casing (10) having a front wall (13) configured to face a back side (6a) of a housing (6) of a metered dose inhaler (2), a back wall (16) opposite the front wall (13) and a side wall (17) extending between the front wall (13) and the back wall (16). An electronic unit (11) is installed inside the casing (10) and comprises a capacitive proximity device (29) having a capacitive sensor antenna (30). The capacitive sensor antenna (30) is placed against or close to an inner surface of the back wall (16) and/or the side wall (17) of the casing (10).
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical information leaflets; Newspapers; Advertising signs of cardboard; Journals; Informational sheets; Educational publications; Printed educational materials; Printed promotional material; Advertisement boards of card; Printed teaching materials; Manuals (handbooks); Printed research reports; Books; Pamphlets; Printed reports; Printed matter; Magazines (periodicals); Prints; Professional magazines Publishing of journals, books and handbooks in the field of medicine; Educational seminars; Organization of seminars; Arranging of presentations for educational purposes; Teaching in the field of medicine; Publication of the results of clinical trials for pharmaceutical preparations; Courses (Training -) relating to science; Organization of conferences and symposia in the field of medical science; Personnel training; Courses (Training -) relating to medicine; Advice relating to medical training; Teaching services relating to the medical field; Conducting of educational seminars relating to medical matters; Teaching; Educational services in the healthcare sector; Education services relating to medicine; Training services in the field of medical disorders and their treatment; Education services relating to pharmacy; Publishing of scientific papers; Publishing and issuing scientific papers in relation to medical technology; Organization of seminars and conventions in the field of medicine; Medical education services; Production of audio/visualpresentations; Organization of training courses; Arranging and conducting of workshops (training); Production of course material distributed at professional seminars; Arranging of lectures; Workshops for educational purposes; Training Pharmaceutical products development; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Biological research; Biological research and analysis; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Advisory services relating to biochemistry; Information technology services for the pharmaceutical and healthcare industries; Biomedical research services; Technological consultancy; Advisory services relating to science; Research on the subject of pharmaceuticals; Consultancy pertaining to pharmacology Pharmaceutical advice; Consulting services relating to health care; Professional consultancy relating to health; Providing medical information; Remote monitoring of medical data for medical diagnosis and treatment; Pharmaceutical services; Providing news and information in the field of medicine; Medical and healthcare clinics; Medical health assessment services; Medical and healthcare services; Providing health care information via a global computer network; Medical screening; Medication counseling; Advisory services relating to pharmaceuticals; Medical information; Medical services for the diagnosis of conditions of the human body
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
An apparatus for administering medicaments includes a dispenser and a portable electronic device. An application loaded in the portable electronic device or in a remote location is configured for: receiving and optionally storing data of the dispenser and a date of reading when reading devices read a machine-readable code at the date of reading and, if the machine-readable code has been read for the first time after manufacturing the dispenser, then: calculating and storing an in-use expiry date from the date of reading and an in-use life period and/or starting an in-use expiry counter. An alert is enabled as a function of the in-use expiry date and/or of the in-use life period, so that the portable electronic device issues the alert when the in-use expiry date is reached or approaching or when the in-use life period is elapsed or about to elapse.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals and natural remedies; Medicated plasters; Nutraceutical preparations for therapeutic or medical purposes; Pharmaceutical compositions; Medicines for human purposes; Chemico-pharmaceutical preparations; Food supplements; Neutraceutical preparations for humans; Pharmaceuticals; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Nutraceuticals for therapeutic purposes; Dietetic substances adapted for medical use; Transdermal patches; Dietary supplements consisting of vitamins; Medicinal healthcare preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal healthcare preparations; Chemico-pharmaceutical preparations; Medicines for human purposes; Pharmaceuticals and natural remedies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal healthcare preparations; Chemico-pharmaceutical preparations; Medicines for human purposes; Pharmaceuticals and natural remedies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals and natural remedies; Medicated plasters; Nutraceutical preparations for therapeutic or medical purposes; Pharmaceutical compositions; Medicines for human purposes; Chemico-pharmaceutical preparations; Food supplements; Neutraceutical preparations for humans; Pharmaceuticals; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Nutraceuticals for therapeutic purposes; Dietetic substances adapted for medical use; Transdermal patches; Dietary supplements consisting of vitamins; Medicinal healthcare preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals and natural remedies; Medicated plasters; Nutraceutical preparations for therapeutic or medical purposes; Pharmaceutical compositions; Medicines for human purposes; Chemico-pharmaceutical preparations; Food supplements; Neutraceutical preparations for humans; Pharmaceuticals; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Nutraceuticals for therapeutic purposes; Dietetic substances adapted for medical use; Transdermal patches; Dietary supplements consisting of vitamins; Medicinal healthcare preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals and natural remedies; Medicated plasters; Nutraceutical preparations for therapeutic or medical purposes; Pharmaceutical compositions; Medicines for human purposes; Chemico-pharmaceutical preparations; Food supplements; Neutraceutical preparations for humans; Pharmaceuticals; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Nutraceuticals for therapeutic purposes; Dietetic substances adapted for medical use; Transdermal patches; Dietary supplements consisting of vitamins; Medicinal healthcare preparations.
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
(R)N(R)NN-(1-(5-methyl-1,2,4- oxadiazol-3-yl)ethyl)quinazolin-4-amine, pharmaceutical compositions containing them and therapeutic use thereof. The salts of the invention may be useful in the treatment of diseases or conditions associated with respiratory diseases, in particular chronic cough.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
26.
TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
The invention relates to pharmaceutical dosage forms comprising a drug having a fast absorption in the gut, which is absorbed in distal intestinal tract including the colon, and for which pulsatile release is necessary to avoid the potential toxicity of the drug continuous absorption. In particular the invention is directed to a dosage form comprising a formulation in form of coated small units to deliver the active ingredient after a programmed time period following oral administration and processes of preparation thereof. In a preferred embodiment the drug is the iron chelator deferiprone.
An apparatus for using a product having an in-use expiry date includes a portable electronic device and a label or tag of the product including a machine-readable code. An application loaded in the portable electronic device or in a remote location is configured for: receiving and optionally storing data of the product and a date of reading when reading devices read the machine-readable code at the date of reading and, if the machine-readable code has been read for the first time after manufacturing the product, then: calculating and storing an in-use expiry date from the date of reading and an in-use life period and/or starting an in-use expiry counter. An alert is enabled as a function of the in-use expiry date and/or of the in-use life period, so that the portable electronic device issues the alert when the in-use expiry date is reached or approaching or when the in-use life period is elapsed or about to elapse.
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Communication via computer terminals, by digital transmission or by satellite; Delivery of digital audio and/or video by telecommunications; Digital communications services; Information transmission services via digital networks; Digital transmission services for audio and video data; Transmission of digital information; Digital audio broadcasting; Automatic transfer of digital data using telecommunications channels; Wireless transfer of data via digital mobile telephony; Transmission of digital files; Digital transmission of data; Transmission of digital audio and video broadcasts over a global computer network; Digital transmission of data via the Internet; Interactive transmission of video over digital networks; Video transmission via digital networks. Consultancy relating to pharmaceutical research and development; Consultancy relating to research and development in the field of therapeutics; Consultancy relating to research in the field of pharmacogenetics; Consultancy pertaining to pharmacology; Development of pharmaceutical preparations and medicines; Information technology services for the pharmaceutical and healthcare industries; Advisory services relating to gene therapy research; Scientific technological services; Scientific and industrial research; Scientific research in the field of pharmacy; Research and development in the pharmaceutical and biotechnology fields; Research and development for the pharmaceutical industry; Scientific research and development; Scientific research relating to biology; Biological research, clinical research and medical research; Research in the field of gene therapy; Genetic testing for scientific research purposes; Scientific research and analysis; Medical and pharmacological research services; Medical research laboratory services; Research and development of vaccines and medicines; Scientific research in the field of social medicine; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information about the results of clinical trials for pharmaceutical products; Providing information on clinical studies via an interactive website; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing scientific information in the field of medical disorders and their treatment; Clinical trials; Conducting clinical trials for pharmaceutical products; Clinical research; Scientific analysis. Providing medical information in the healthcare sector; Providing health information; Health advice and information services; Medical services for the treatment of conditions of the human body; Medical services; Medical information; Pharmaceutical advice; Pharmaceutical services; Advisory services relating to degenerative diseases; Advisory services relating to the treatment of degenerative diseases; Consulting services relating to health care; Consultancy and information services relating to pharmaceutical products; Health care in the nature of health maintenance organizations; Medical consultations; Provision of pharmaceutical information; Information services relating to health care.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Communication via computer terminals, by digital transmission or by satellite; Delivery of digital audio and/or video by telecommunications; Digital communications services; Information transmission services via digital networks; Digital transmission services for audio and video data; Transmission of digital information; Digital audio broadcasting; Automatic transfer of digital data using telecommunications channels; Wireless transfer of data via digital mobile telephony; Transmission of digital files; Digital transmission of data; Transmission of digital audio and video broadcasts over a global computer network; Digital transmission of data via the Internet; Interactive transmission of video over digital networks; Video transmission via digital networks. Consultancy relating to pharmaceutical research and development; Consultancy relating to research and development in the field of therapeutics; Consultancy relating to research in the field of pharmacogenetics; Consultancy pertaining to pharmacology; Development of pharmaceutical preparations and medicines; Information technology services for the pharmaceutical and healthcare industries; Advisory services relating to gene therapy research; Scientific technological services; Scientific and industrial research; Scientific research in the field of pharmacy; Research and development in the pharmaceutical and biotechnology fields; Research and development for the pharmaceutical industry; Scientific research and development; Scientific research relating to biology; Biological research, clinical research and medical research; Research in the field of gene therapy; Genetic testing for scientific research purposes; Scientific research and analysis; Medical and pharmacological research services; Medical research laboratory services; Research and development of vaccines and medicines; Scientific research in the field of social medicine; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information about the results of clinical trials for pharmaceutical products. Providing medical information in the healthcare sector; Providing health information; Health advice and information services; Medical services for the treatment of conditions of the human body; Medical services; Medical information; Pharmaceutical advice; Pharmaceutical services; Advisory services relating to degenerative diseases; Advisory services relating to the treatment of degenerative diseases; Consulting services relating to health care; Consultancy and information services relating to pharmaceutical products; Health care in the nature of health maintenance organizations; Medical consultations; Provision of pharmaceutical information; Information services relating to health care.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal healthcare preparations; Chemico-pharmaceutical preparations; Medicines for human purposes; Pharmaceuticals and natural remedies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal healthcare preparations; Chemico-pharmaceutical preparations; Medicines for human purposes; Pharmaceuticals and natural remedies.
33.
PROCESS FOR THE PREPARATION OF A PULMONARY SURFACTANT
This invention is directed to a process for the preparation of an exogenous pulmonary surfactant, in particular a modified natural surfactant or a reconstituted surfactant, wherein the final filtration step is performed without the use of chlorinated solvents. The invention is also directed to the product as obtained by said process, and to the corresponding pharmaceutical compositions.
The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention generally relates to compounds (I) inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention generally relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof; the compounds of the invention may be useful for instance in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
38.
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Organising of competitions for education; Training in the field of medicine; Production of audio/visual presentations; Publishing of journals, books and handbooks in the field of medicine; Publication of the results of clinical trials for pharmaceutical preparations; Publishing scientific papers in relation to medical technology; Training services in the field of medical disorders and their treatment; Medical training and teaching; Advice relating to medical training; Organization of seminars and conventions in the field of medicine; Conducting of educational seminars relating to medical matters; Arranging of award ceremonies; Arranging of award ceremonies to recognise bravery; Arranging of award ceremonies to recognise achievement; Arranging, conducting and organisation of conferences; Organisation of conferences, exhibitions and competitions; Organisation of seminars and conferences; Arranging and conducting of conferences and congresses; Organisation of conferences and symposia in the field of medical science; Education services relating to medicine; Publishing and issuing scientific papers in relation to medical technology; Courses (Training -) relating to research and development. Scientific research and analysis; Medical research; Biological research and analysis; Research and development in the pharmaceutical and biotechnology fields; Chemical research and analysis services; Information technology services for the pharmaceutical and healthcare industries; Genetic testing for scientific research purposes; Biological research, clinical research and medical research; Development of pharmaceutical preparations and medicines; Research and development in the field of microorganisms and cells; Providing scientific information in the field of medical disorders and their treatment; Clinical research; Scientific research in the field of pharmacy; Scientific research relating to biology; Scientific services relating to the isolation and cultivation of human tissues and cells; Bacteriological research and analysis; Medical and pharmacological research services; Advisory services relating to science; Technological consultancy; Biology consultancy; Biochemistry consultancy; Consultancy relating to pharmaceutical research and development; Pharmaceutical product evaluation; Pharmaceutical research services; Pharmaceutical products development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Consulting services relating to health care; Providing health information; Providing medical information in the healthcare sector; Medical services; Medical information; Medical consultations; Information services relating to health care; Health counselling; Pharmacy advice; Professional consultancy relating to health; Professional consultancy relating to health care; Providing medical information; Providing information relating to medical services; Providing news and information in the field of medicine; Medical services for the treatment of conditions of the human body; Medical screening; Pharmaceutical services; Medical health assessment services.
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising signs of cardboard; Printed teaching materials; Informational sheets; Printed promotional material; Advertisement boards of card; Pharmaceutical information leaflets; Newspapers; Books; Manuals [handbooks]; Pamphlets; Professional magazines; Journals; Educational publications; Printed educational materials; Magazines [periodicals]; Printed reports; Printed research reports; Printed matter; Prints. Conducting of educational seminars relating to medical matters; Advice relating to medical training; Courses (Training -) relating to science; Courses (Training -) relating to medicine; Arranging and conducting of workshops [training]; Training; Personnel training; Teaching; Education services relating to pharmacy; Publishing of scientific papers; Production of audio/visual presentations; Publishing of journals, books and handbooks in the field of medicine; Publication of the results of clinical trials for pharmaceutical preparations; Publishing and issuing scientific papers in relation to medical technology; Organisation of conferences and symposia in the field of medical science; Organisation of seminars; Organization of seminars and conventions in the field of medicine; Organisation of training courses; Arranging of lectures; Workshops for educational purposes; Education services relating to medicine; Arranging of presentations for educational purposes; Educational seminars; Training services in the field of medical disorders and their treatment; Educational services in the healthcare sector; Production of course material distributed at professional seminars; Teaching in the field of medicine; Medical education services; Teaching services relating to the medical field. Advisory services relating to science; Technological consultancy; Consultancy pertaining to pharmacology; Consultancy relating to pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing information about the results of clinical trials for pharmaceutical products; Biological research; Biological research and analysis; Advisory services relating to biochemistry; Research on the subject of pharmaceuticals; Pharmaceutical product evaluation; Pharmaceutical products development; Biomedical research services; Information technology services for the pharmaceutical and healthcare industries; Research and development for the pharmaceutical industry. Consulting services relating to health care; Pharmaceutical advice; Medication counseling; Professional consultancy relating to health; Providing news and information in the field of medicine; Providing health care information via a global computer network; Medical information; Remote monitoring of medical data for medical diagnosis and treatment; Providing medical information; Medical and healthcare services; Medical services for the diagnosis of conditions of the human body; Medical screening; Pharmaceutical services; Medical health assessment services; Medical and healthcare clinics; Advisory services relating to pharmaceuticals.
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising signs of cardboard; Printed teaching materials; Informational sheets; Printed promotional material; Advertisement boards of card; Pharmaceutical information leaflets; Newspapers; Books; Manuals [handbooks]; Pamphlets; Professional magazines; Journals; Educational publications; Printed educational materials; Magazines [periodicals]; Printed reports; Printed research reports; Printed matter; Prints. Conducting of educational seminars relating to medical matters; Advice relating to medical training; Courses (Training -) relating to science; Courses (Training -) relating to medicine; Arranging and conducting of workshops [training]; Training; Personnel training; Teaching; Education services relating to pharmacy; Publishing of scientific papers; Production of audio/visual presentations; Publishing of journals, books and handbooks in the field of medicine; Publication of the results of clinical trials for pharmaceutical preparations; Publishing and issuing scientific papers in relation to medical technology; Organisation of conferences and symposia in the field of medical science; Organisation of seminars; Organization of seminars and conventions in the field of medicine; Organisation of training courses; Arranging of lectures; Workshops for educational purposes; Education services relating to medicine; Arranging of presentations for educational purposes; Educational seminars; Training services in the field of medical disorders and their treatment; Educational services in the healthcare sector; Production of course material distributed at professional seminars; Teaching in the field of medicine; Medical education services; Teaching services relating to the medical field. Advisory services relating to science; Technological consultancy; Consultancy pertaining to pharmacology; Consultancy relating to pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing information about the results of clinical trials for pharmaceutical products; Biological research; Biological research and analysis; Advisory services relating to biochemistry; Research on the subject of pharmaceuticals; Pharmaceutical product evaluation; Pharmaceutical products development; Biomedical research services; Information technology services for the pharmaceutical and healthcare industries; Research and development for the pharmaceutical industry. Consulting services relating to health care; Pharmaceutical advice; Medication counseling; Professional consultancy relating to health; Providing news and information in the field of medicine; Providing health care information via a global computer network; Medical information; Remote monitoring of medical data for medical diagnosis and treatment; Consulting services relating to health care; Providing medical information; Medical and healthcare services; Medical services for the diagnosis of conditions of the human body; Medical screening; Pharmaceutical services; Medical health assessment services; Medical and healthcare clinics; Advisory services relating to pharmaceuticals.
42.
METHOD, APPARATUS, AND MEDIUM FOR POINT CLOUD CODING
Embodiments of the present disclosure provide a method for point cloud coding. The method comprises: obtaining, during a conversion between a current frame of a point cloud sequence and a bit-stream of the point cloud sequence, motion information of the current frame; determining a binarized representation of the motion information, the binarized representation at least reflecting an absolute value of the motion information; and performing the conversion based on the binarized representation of the motion information. Compared with the conventional solution, the proposed method can advantageously improve the accuracy of motion information coding and coding quality.
H04N 19/184 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding characterised by the coding unit, i.e. the structural portion or semantic portion of the video signal being the object or the subject of the adaptive coding the unit being bits, e.g. of the compressed video stream
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
45.
PHOSPHOGLICERATE DEHYDROGENASE INHIBITORS FOR THE TREATMENT OF FIBROSIS
The present invention relates to a new therapeutic use of compounds of PHGDH inhibitors of general formula (I), for the prevention and/or treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF). The invention is related also the use of the pharmaceutical compositions and combinations comprising said compounds for the prevention and/or treatment of fibrosis and in particular IPF.
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present invention relates to a new therapeutic use of compounds of PHGDH inhibitors of general formula (I), for the prevention and/or treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF). The invention is related also the use of the pharmaceutical compositions and combinations comprising said compounds for the prevention and/or treatment of fibrosis and in particular IPF.
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
49.
8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
50.
PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
51.
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention generally relates to compounds of formula (I) inhibiting the transforming growth factor beta (TGF beta) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof; the compounds of the invention may be useful for instance in the treatment of many diseases, disorder, or condition associated with ALK5 signaling pathway.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
The present invention relates to a combined therapy for use in treatment and prevention of treatment and prevention of brain injury, in particular ischemic and/or hypoxic brain lesions, including but not limited to hypoxic-ischemic encephalopathy, preferably in a neonatal subject either at term or at preterm.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of ACROMEGALY disease Downloadable electronic publications in the nature of medical guides in the field of ACROMEGALY disease Education services, namely, providing non-downloadable webinars on the topics of ACROMEGALY disease and healthcare Providing scientific information in the field of medical disorders and their treatment Providing a website featuring information about health, namely, ACROMEGALY disease, medical care and health care; providing health and educational information about ACROMEGALY disease; Medical services; Providing health information; Providing medical information in the healthcare sector; Human healthcare services, namely, disease management programs; support services for people affected by genetic diseases, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Medical information; Information services relating to health care
The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular the invention is directed to a modified-release formulation in form of mini-tablets suitable for twice-a-day oral administration for the treatment of diseases which cause an overload of iron for example, thalassemia, sickle cell anemia, hemochromatosis, and myelodysplasia, or for the prevention and/or treatment of diseases which are caused by an overload of iron. The invention is also directed to methods of making said formulation.
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, developing, arranging and conducting classes, courses, seminars, conferences, symposia, workshops, presentations, conventions in the field of pharmacy, medicine, medical science and medical matters and distribution of training materials in connection therewith; Training in the field of medicine; Educational instruction in the field of medical science; Conducting of educational seminars relating to medical matters; Provision of training courses in the field of medical science; Providing courses of instruction in the field of medicine; Workshops for training purposes in the field of medical science; Medical training and teaching; Educational seminars in the field of medical science; Organization of seminars and conventions in the field of medicine; Arranging and conducting of seminars and workshops in the field of medical science; Organization of conferences and symposia in the field of medical science; Arranging of conferences in the field of medical science; Personnel training in the field of medical science; Arranging of presentations for educational purposes by educational speakers in the field of medical science; Training services in the field of medical disorders and their treatment; Education services relating to medicine in the nature of medical and nursing schools; Education services relating to pharmacy, namely, providing classes, courses and seminars in the field of medicine and pharmaceuticals; Adult education services relating to pharmacy, namely, providing continuing medical education courses; Medical education services in the nature of medical and nursing schools; Providing information and advice in the field of medical training; Provision of medical instruction courses; Publishing of journals, books and handbooks in the field of medicine; Publishing scientific papers in relation to medical technology; Production of audio/visual presentations in the field of medical science; Publishing of course material in the nature of journals, books and handbooks in the field of medical science distributed at professional seminars
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, developing, arranging and conducting classes, courses, seminars, conferences, symposia, workshops, presentations, conventions in the field of pharmacy, medicine, medical science and medical matters and distribution of training materials in connection therewith; Training in the field of medicine; Educational instruction in the field of medical science; Conducting of educational seminars relating to medical matters; Provision of training courses in the field of medical science; Providing courses of instruction in the field of medicine; Workshops for training purposes in the field of medical science; Medical training and teaching; Educational seminars in the field of medical science; Organization of seminars and conventions in the field of medicine; Arranging and conducting of seminars and workshops in the field of medical science; Organization of conferences and symposia in the field of medical science; Arranging of conferences in the field of medical science; Personnel training in the field of medical science; Arranging of presentations for educational purposes by educational speakers in the field of medical science; Training services in the field of medical disorders and their treatment; Education services relating to medicine in the nature of medical and nursing schools; Education services relating to pharmacy, namely, providing classes, courses and seminars in the field of medicine and pharmaceuticals; Adult education services relating to pharmacy, namely, providing continuing medical education courses; Medical education services in the nature of medical and nursing schools; Providing information and advice in the field of medical training; Provision of medical instruction courses; Publishing of journals, books and handbooks in the field of medicine; Publishing scientific papers in relation to medical technology; Production of audio/visual presentations in the field of medical science; Publishing of course material in the nature of journals, books and handbooks in the field of medical science distributed at professional seminars
61.
CAPSULE INHALER FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a drug product or a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a drug product or a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
65.
DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
67.
DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
68.
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. 5 The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
69.
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A dry powder inhaler comprises an inhalation channel (8) connected to a mouthpiece (4), a container (7) for storing a powdered medicament, a de-agglomerator (25) with a vortex chamber (26) located at an end of the inhalation channel (8), a metering device (14) comprising a shuttle (16) having a dosing recess (15). The shuttle (16) is movable between a filling position, in which the dosing recess (15) is in alignment with an opening (17) of the container (7), and an inhalation position, in which the dosing recess (15) is in alignment with the vortex chamber (26). The opening (17) of the container (7) is elongated along a major axis (Y-Y) and the dosing recess (15) is elongated along a main axis (X-X) and, when the shuttle (16) is in the filling position, an edge (27) of the opening (17) of the container (7) encloses the dosing recess (15).
A dry powder inhaler includes an inhalation channel connected to a mouthpiece, a container for storing a powdered medicament, a de-agglomerator with a vortex chamber located at an end of the inhalation channel, a metering device including a shuttle having a dosing recess. The shuttle is movable between a filling position, in which the dosing recess is in alignment with an opening of the container, and an inhalation position, in which the dosing recess is in alignment with the vortex chamber. The opening of the container is elongated along a major axis and the dosing recess is elongated along a main axis and, when the shuttle is in the filling position, an edge of the opening of the container encloses the dosing recess.
The present invention relates to the use of IL-8 as a biomarker of clinical response to a compound of formula (I), (I). It refers to a compound of formula (I) or a pharmaceutical composition thereof for use in a method of treatment of a disorder susceptible to treatment with a PDE4 inhibitor, wherein the method comprises the step of measuring the value of IL-8 in the blood of a subject and to a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition.
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 419/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods of preparing such compounds, and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DPP1 receptors mechanisms, in particular respiratory diseases.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 237/34 - Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
79.
(AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
80.
5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS
The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H- imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis. An example with good activity is e.g. example 5: 2-(dimethylamino) -N-(2-fluoro-5-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H imidazo[1,2- a]imidazol-5-yl)phenyl)acetamide (Formula IA). Pharmacological data is provided: (Table 3)
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 43/00 - Drugs for specific purposes, not provided for in groups
81.
A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
The present invention generally relates to pharmaceutical composition comprising a LABA agent, a LAMA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
82.
A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
The present invention generally relates to pharmaceutcial composition comprising a LABA agent, optionally in combination with other active ingredients, a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
83.
A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
The present invention generally relates to pharmaceutcial composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
84.
PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
85.
PRESSURED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION
The present invention generally relates to an aerosol formulation comprising formoterol and beclomethasone dipropionate, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to the crystal Form 2 of the compound of formula (I), to the process for its isolation and to the pharmaceutical compositions thereof. The present invention also relates to the crystal Form 2 of the compound of formula (I) for use as a medicament and for the manufacture of a medicament for the prevention and/or treatment of an inflammatory respiratory or obstructive respiratory disease.
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
The present invention relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The invention is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit delayed release properties when administered as either whole or half tablets. In particular, the invention is directed to delayed release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The invention is also directed to methods of making and using the same.
The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the invention is also directed to delayed release tablets suitable either for twice daily administration or once daily administration. The invention is also directed to methods of making and using the same.
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Printed matter; Printed publications; Books; Manuals [handbooks]; Pharmaceutical information leaflets; Printed research reports; Printed reports; Information books; Educational publications; Periodicals; Educational and instructional material. Training; Educational instruction; Conducting of educational seminars relating to medical matters; Provision of training courses; Courses (Training -) relating to medicine; Workshops for training purposes; Medical training and teaching; Educational seminars; Organization of seminars and conventions in the field of medicine; Arranging and conducting of seminars and workshops; Organisation of conferences and symposia in the field of medical science; Arranging of conferences; Personnel training; Arranging of presentations for educational purposes; Training services in the field of medical disorders and their treatment; Education services relating to medicine; Education services relating to pharmacy; Adult education services relating to pharmacy; Medical education services; Advice relating to medical training; Provision of medical instruction courses; Publishing of journals, books and handbooks in the field of medicine; Publishing scientific papers in relation to medical technology; Training in the field of medicine; Publication of the results of clinical trials for pharmaceutical preparations; Production of audio/visual presentations; Production of course material distributed at professional seminars. Consultancy relating to pharmaceutical research and development; Consultancy relating to research and development in the field of therapeutics; Consultancy relating to research in the field of pharmacogenetics; Consultancy pertaining to pharmacology; Development of pharmaceutical preparations and medicines; Information technology services for the pharmaceutical and healthcare industries; Advisory services relating to gene therapy research; Scientific technological services; Scientific and industrial research; Scientific research in the field of pharmacy; Research and development in the pharmaceutical and biotechnology fields; Research and development for the pharmaceutical industry; Scientific research and development; Scientific research relating to biology; Biological research, clinical research and medical research; Research in the field of gene therapy; Genetic testing for scientific research purposes; Scientific research and analysis; Medical and pharmacological research services; Medical research laboratory services; Research and development of vaccines and medicines; Scientific research in the field of social medicine; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information about the results of clinical trials for pharmaceutical products; Providing information on clinical studies via an interactive website; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing scientific information in the field of medical disorders and their treatment; Clinical trials; Conducting clinical trials for pharmaceutical products; Clinical research; Scientific analysis; Provision of information and data relating to medical and veterinary research and development.
The present disclosure relates to stable formulations of tissue-type plasminogen activator (tPA). In particular, the disclosure relates to specific new formulations, methods of preparing them and methods of using them.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
93.
AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
94.
A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of at least two inorganic acids, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention is directed to polypeptides having the properties of both SP-C and SP-B surfactant proteins and to the corresponding reconstituted surfactants. The invention is also directed to the pharmaceutical compositions thereof and to their use for the treatment or prophylaxis of neonatal respiratory distress syndrome (RDS) or other respiratory disorders such as acute RDS.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 11/00 - Drugs for disorders of the respiratory system
96.
AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and medicinal preparations for the treatment of respiratory diseases; medical preparations and products for the treatment of respiratory diseases
The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
